Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:42 PM
Ignite Modification Date: 2025-12-24 @ 11:42 PM
NCT ID: NCT05898451
Eligibility Criteria: Inclusion Criteria: * Patients who have exhausted standard methods of treatment. * Morphological (histological or cytological) confirmation of the diagnosis. * Age no more than 75 years. * General condition 0-2 (WHO). * Estimated life expectancy of at least 3 months. * Consent to treatment under this protocol. * The number of granulocytes is more than 2000/mm, platelets are more than 150000/mm. * The level of creatinine should not exceed 1.5 norms, liver enzymes (ALT, AST and alkaline phosphatase) should not exceed 3 norms. * For common disease, patients should receive standard treatment earlier. Exclusion Criteria: * Severe manifestations of cardiovascular diseases in the past and at present (myocardial infarction, hypertension, stroke, phlebothrombosis, coronary insufficiency requiring drug control, etc.). * Peptic ulcer of the stomach, duodenal ulcer (in the acute phase), uncorrected diabetes mellitus. * Mental illness preventing understanding of the treatment plan. * Pregnancy. * Metastases of a malignant tumor in the brain (according to clinical data). * Chronic use of corticosteroids or immunosuppressants. * Various neurological diseases that prevent this treatment. * Known allergic reactions and/or other significant allergic conditions. * Any immunotherapy within the last 6 weeks prior to enrollment in the study.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT05898451
Study Brief:
Protocol Section: NCT05898451